Artificial intelligence is increasingly shaping how new medicines get discovered, and two recent items point to the trend from different angles.
According to Fortune India, Mankind Pharma has entered a collaboration with Armenian firm Denovo Sciences to run an AI-led drug discovery programme. The tie-up pairs an established pharmaceutical company with a specialist AI partner, reflecting a broader pattern of drugmakers looking outside their own labs for computational expertise.
Meanwhile, a press release carried by USA Today frames AI as one of several forces drawing investor attention to a group of biotech companies. It reports that clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are together creating what it calls a steady stream of catalysts that Wall Street investors will be watching closely.
Taken together, the two sources sketch a market in which AI has moved past being a talking point and into concrete business activity: partnerships between pharma companies and AI-focused startups, and investor interest keyed partly to whether AI discovery platforms deliver results.
The details available are limited. Neither source, as presented here, specifies financial terms, timelines, or which diseases the programmes target, and the claims about investor interest come from a press release rather than independent reporting.
Still, the direction is consistent with a wider shift in the industry. Drug discovery has long been slow and expensive, with most candidates failing before reaching patients. If AI tools can help identify promising molecules faster or more cheaply, that could reshape both how medicines are developed and where investors place their bets.
Why it matters: these deals and market signals suggest AI is starting to change the economics of finding new drugs, an industry where speed and success rates directly affect which treatments reach patients.